Magazine Article | August 1, 2023

Novo Nordisk Returns To Growth, With Growing Pains

Source: Life Science Leader

By Ben Comer, Chief Editor, Life Science Leader

Semaglutide, the active ingredient in Novo Nordisk’s Ozempic, Rybelsus, and Wegovy, has been a game changer for the 100-year-old Danish company. Novo is now entering “what we internally call chapter two of our transformation and evolution into new therapy areas,” says Doug Langa, EVP, North America operations and president of Novo Nordisk. Revenues in North America were up 41% in the first quarter of 2023, due in no small part to the growing demand for safe and effective obesity products.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader